LSNE is a leading contract development and manufacturing organisation specialising in sterile lyophilization and fill & finish of drugs and devices, serving a range of pharmaceutical, biotech and medical device customers. Find out how we are supporting their plans to increase its manufacturing footprint and expand its product offering…
LSNE
Why we backed them
- To back a leader in an attractive niche with key competitive advantages
- To support a strong management team in a rapidly growing market which is predicted to grow 7-9% p.a.
- To benefit from a market that has high barriers to entry given requirements of technical expertise, regulatory track record and capital investment
The investment strategy
- To vertically integrate into the attractive active pharmaceutical ingredients (“API”) category
- To broaden the manufacturing footprint across geographies
- To expand capacity to enable further commercial-level contracts and extend capabilities to better serve both US and European commercial customers
The metrics
2017
Acquisition year
20 years
Quality regulatory history
3
FDA approved facilities